Research Summaries

Chemotherapy Plus Either Bevacizumab or Cetuximab Are Equally Effective for Metastatic Colorectal Cancer

ASCO Annual Meeting
June 1, 2014

In a large, ongoing study, results indicate that two common treatment regimens approved by the U.S. Food and Drug Administration are equally effective for metastatic colorectal cancer. Metastatic colorectal cancer is cancer that has spread to other parts of the body.

Second-Line Treatment with Ramucirumab and Chemotherapy Lengthens Lives of Patients with NSCLC

ASCO Annual Meeting
May 31, 2014

Results from a new study show that combining the targeted therapy ramucirumab (Cyramza) with standard chemotherapy lengthens the lives of patients with non-small cell lung cancer (NSCLC). Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, ramucirumab targets a protein called VEGF receptor 2, blocking the growth of new blood vessels in the tumor that are needed for the tumor to grow and spread.

For Older Patients with CLL, Ibrutinib May Be an Effective New Treatment Option

ASCO Annual Meeting
May 31, 2014

Early results from an ongoing study show that ibrutinib (Imbruvica) keeps relapsed chronic lymphocytic leukemia (CLL) from worsening for longer than ofatumumab (Arzerra), a standard treatment option for relapsed or refractory CLL. CLL is the most common type of leukemia in adults. Relapsed CLL is when the disease returns after remission, a time when there are no signs or symptoms of the disease. Refractory CLL is when the disease worsens despite treatment.

Lenvatinib Could Be a New Option for Patients with Differentiated Radioiodine-Resistant Thyroid Cancer

ASCO Annual Meeting
May 31, 2014

Results from a recent study show that the drug lenvatinib could become a new, effective treatment option for patients with differentiated thyroid cancer that is resistant to standard radioiodine (RAI) therapy. Differentiated thyroid cancer is the most common subtype of thyroid cancer. It is generally curable with surgery and RAI. However, about 5% to 15% of patients with this subtype develop resistance to RAI, which means that it is no longer able to control the cancer’s growth.

Pages

Subscribe to RSS - Research Summaries